JDRF Pipeline September 2023

This is a newsletter from the JDRF. I am including the contents.- Happy Tuesday!

  • In a newly published study in the New England Journal of Medicine, semaglutide (brand names Ozempic®, Rybelsus®, and Wegovy®) improved blood-sugar control and decreased mealtime and basal insulin requirements in ten newly diagnosed individuals.
  • Lonza and Vertex broke ground on a manufacturing facility in New Hampshire that will support the development and commercialization of Vertex’s T1D cell therapies portfolio. JDRF CEO Aaron Kowalski was in attendance along with U.S. Senator and Senate Diabetes Caucus Co-Chair Jeanne Shaheen.
  • Injections, whether insulin or other medications such as Ozempic and Wegovy, can be painful and uncomfortable. Check out some tips to make them go more smoothly.
  • JDRF has partnered with Antidote and Beyond Type 1 to launch the first-ever Spanish language clinical trial search tool for people living with type 1 diabetes (T1D). This tool will make it easier for Spanish-speaking members of the T1D community to find and enroll in clinical trials, and help drive research progress forward. Learn more.
  • JDRF se ha asociado con Antidote y Beyond Type 1 para lanzar la primera herramienta de búsqueda de ensayos clínicos en español para personas que viven con diabetes tipo 1 (DT1). Esta herramienta facilitará a los miembros hispanohablantes de la Comunidad de diabetes tipo 1 a encontrar ensayos clínicos e inscribirse en ellos, y ayudar a impulsar el progreso de la investigación. Obtenga más información aquí.
  • Roche announced that it received clearance for the Accu-Chek Solo® micropump system. The micropump is cleared as an alternate controller enabled (ACE) pump meaning that it could be integrated into an automated insulin delivery (AID) system in the future.
  • Novo Nordisk **launched MyInsulinRx**™, a cash offer program in which eligible patients with a prescription can get a 30-day supply (up to three vials or two packs of FlexPen®/FlexTouch®/PenFill® pens) of any combination of current Novo Nordisk insulins for $35.
  • Abbott is acquiring Bigfoot Biomedical, maker of Bigfoot Unity, an insulin management system. Bigfoot is led by former JDRF CEO Jeffrey Brewer, and the JDRF T1D Fund invested in Bigfoot.
  • Sidra Medicine (a member of Qatar Foundation) has been awarded a grant from JDRF to support the establishment of a program in Qatar that combines autoantibody and genetic screening for children with T1D.
1 Like

Thank you @joe. I am particularly intrigued by the Accu-chek Solo micro-pump. When I got my very first pump it was my endo’s office that provided most of my support - not just with settings but how to use it overall. Jumping ahead to when I got my Omnipod5 last year, I was my doctor’s first patient to use it and I got my training before she and her office did!
As new devices come out, and improvements are made by leaps and bounds to existing ones, I imagine there will be an even greater need for Certified Diabetes Care and Education Specialists/Certified Diabetes Educators.
We often lament the lack of understanding by medical professionals of the unique challenges we face, so for those on the younger end of the age scale who are thinking about careers, this could be a good choice to consider. Diabetes is increasing (I don’t have statistics for Type1 vs Type2) so there will be the need.
I knew I have stayed off topic so moderators I’ll shut up now :blush:.

1 Like